ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,673,238 | -37.6% | 232,963 | -12.2% | 0.00% | 0.0% |
| Q2 2023 | $7,489,304 | +45.0% | 265,484 | -11.6% | 0.00% | 0.0% |
| Q1 2023 | $5,164,988 | +6.7% | 300,290 | +24.9% | 0.00% | 0.0% |
| Q4 2022 | $4,840,447 | +83.0% | 240,340 | +96.8% | 0.00% | – |
| Q3 2022 | $2,645,000 | -69.6% | 122,135 | -60.5% | 0.00% | -100.0% |
| Q2 2022 | $8,696,000 | -33.7% | 309,467 | +8.9% | 0.00% | 0.0% |
| Q1 2022 | $13,115,000 | -21.0% | 284,248 | +44.0% | 0.00% | -50.0% |
| Q4 2021 | $16,592,000 | +195.2% | 197,389 | +134.0% | 0.00% | +100.0% |
| Q3 2021 | $5,621,000 | +29.1% | 84,351 | +3.1% | 0.00% | – |
| Q2 2021 | $4,353,000 | +10.8% | 81,827 | -9.6% | 0.00% | – |
| Q1 2021 | $3,929,000 | +57.4% | 90,542 | +88.4% | 0.00% | – |
| Q4 2020 | $2,496,000 | +155.0% | 48,064 | +60.6% | 0.00% | – |
| Q3 2020 | $979,000 | +20.3% | 29,932 | +76.7% | 0.00% | – |
| Q2 2020 | $814,000 | – | 16,939 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |